Trastuzumab deruxtecan
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Small Cell Lung Cancer
Conditions
Non-Small Cell Lung Cancer
Trial Timeline
Mar 19, 2021 → Aug 23, 2024
NCT ID
NCT04644237About Trastuzumab deruxtecan
Trastuzumab deruxtecan is a phase 2 stage product being developed by Daiichi Sankyo for Non-Small Cell Lung Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT04644237. Target conditions include Non-Small Cell Lung Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Non-Small Cell Lung Cancer were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (19)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07015697 | Phase 1 | Recruiting |
| NCT06750484 | Phase 2 | Recruiting |
| NCT05982678 | Phase 2 | Recruiting |
| NCT06386263 | Pre-clinical | Completed |
| NCT06210776 | Pre-clinical | Recruiting |
| NCT05950945 | Phase 3 | Recruiting |
| NCT05993234 | Pre-clinical | Recruiting |
| NCT05945732 | Pre-clinical | Recruiting |
| NCT05458401 | Pre-clinical | Completed |
| NCT05246514 | Phase 2 | Active |
| NCT04989816 | Phase 2 | Completed |
| NCT04739761 | Phase 3 | Active |
| NCT04644237 | Phase 2 | Completed |
| NCT04639219 | Phase 2 | Active |
| NCT04482309 | Phase 2 | Recruiting |
| NCT04752059 | Phase 2 | Completed |
| NCT04420598 | Phase 2 | Completed |
| NCT04014075 | Phase 2 | Completed |
| NCT03505710 | Phase 2 | Terminated |
Competing Products
20 competing products in Non-Small Cell Lung Cancer